amwell Bundle
Who Really Owns Amwell?
Understanding the ownership structure of a company is crucial for investors and analysts alike. Amwell, a pioneer in telehealth, has experienced significant shifts in its ownership since its inception. From its founding to its public listing, the amwell SWOT Analysis reveals critical insights into its strategic direction and market position.
This report explores the evolution of amwell ownership, shedding light on the key players shaping its future. Knowing who owns Amwell is essential for anyone looking to understand the company's trajectory, from its amwell parent company dynamics to the influence of its amwell investors. We'll examine the amwell stock ownership and the implications for its long-term success, including the amwell company history and the impact of being amwell publicly traded.
Who Founded amwell?
The telehealth company, Amwell, was established in 2006. The founders of the amwell company were brothers Drs. Ido Schoenberg and Roy Schoenberg. Their combined medical and entrepreneurial backgrounds set the stage for the company's future.
The Schoenberg brothers, both medical school graduates from Israel, brought a wealth of experience to their venture. Prior to Amwell, Ido co-founded iMDsoft in 1996, while Roy founded CareKey. These previous ventures provided the brothers with valuable insights into the healthcare and technology sectors.
After selling CareKey in 2005, the brothers launched Amwell, initially based in Boston. This strategic move allowed them to leverage their expertise in healthcare management and software development to address the growing demand for telehealth solutions.
Founding Team
Drs. Ido and Roy Schoenberg, both medical doctors, founded Amwell. Their combined medical and entrepreneurial backgrounds were instrumental in the company's inception.
Early Ventures
Ido co-founded iMDsoft in 1996, and Roy founded CareKey. These experiences provided valuable insights into healthcare technology.
Initial Funding
Amwell secured over $500 million from investors in its early stages. Key investors included Anthem, Philips, and Allianz.
Series C Financing
In May 2020, Amwell raised $194 million in Series C financing. This round included participation from early investors and strategic partners.
Early Backing
Early investors included major players in the healthcare and insurance industries. Strategic partnerships were key to the company's growth.
Company Location
The company was initially based in Boston, Massachusetts. This location provided access to a strong talent pool and a vibrant tech ecosystem.
The early amwell ownership structure involved significant backing from strategic investors. While the exact equity split at the company’s inception isn't publicly detailed, Amwell raised substantial funds from investors like Anthem, Philips, and Allianz. In May 2020, Amwell secured $194 million in Series C financing, with continued support from early investors and partners such as Allianz X and Takeda. For more insights into the competitive landscape, you can explore the Competitors Landscape of amwell.
Key Takeaways
Amwell's early success was driven by its founders' expertise and strategic investments.
- Founded by Drs. Ido and Roy Schoenberg.
- Raised over $500 million from early investors.
- Secured $194 million in Series C financing in May 2020.
- Early investors included Anthem, Philips, and Allianz.
- The company's headquarters were established in Boston.
amwell SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has amwell’s Ownership Changed Over Time?
The evolution of amwell ownership has been marked by significant events, most notably its initial public offering (IPO) and subsequent market performance. The amwell company went public in September 2020, listing on the New York Stock Exchange (NYSE) under the ticker AMWL. Prior to the IPO, in August 2020, Google invested $100 million in the company through a private placement, signaling early confidence in the telehealth provider. However, since its IPO, the market capitalization of amwell has experienced a substantial decline.
As of June 6, 2025, the market capitalization of amwell stood at $108.64 million, a dramatic decrease from its initial valuation of $3.96 billion. This represents a decrease of 97.26%, reflecting challenges and shifts in the telehealth market. This evolution has significantly impacted the ownership structure, influencing the holdings of both institutional and insider shareholders.
| Ownership Category | Percentage | Shares |
|---|---|---|
| Institutional Shareholders | 38.62% | 6,774,811 |
| American Well Insiders | 111.47% | - |
| Retail Investors | 0.00% | - |
As of June 5, 2025, amwell is owned by 38.62% institutional shareholders, 111.47% American Well insiders, and 0.00% retail investors. Key institutional shareholders include Senvest Management, LLC, Morgan Stanley, Caledonia (Private) Investments Pty Ltd, and Vanguard Group Inc. The insider ownership is significant, with co-founders Roy Schoenberg and Ido Schoenberg holding substantial stakes. Understanding the amwell ownership structure is crucial for investors looking at the company's future. For more insights, consider reading about the Growth Strategy of amwell.
Key Insider Holdings
The co-founders of amwell hold significant stakes in the company, indicating their continued commitment. Roy Schoenberg owns 2.17 million shares (13.70%), valued at approximately $15.08 million. Ido Schoenberg owns 1.91 million shares (12.09%), valued at approximately $13.30 million.
- Keith Anderson (10.81%)
- Rivka Goldwasser (8.85%)
- Brendan P. O'Grady (5.40%)
- Robert Thomas Webb (4.70%)
- Bradford Gay (4.66%)
amwell PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on amwell’s Board?
The current Board of Directors for the amwell company consists of 9 members. They are organized into three classes, each serving staggered three-year terms. Ido Schoenberg, MD, one of the co-founders, holds the positions of Chairman and CEO. Roy Schoenberg, MD, MPH, also a co-founder, serves as the Executive Vice Chairman.
Recent information indicates that the company is publicly traded, which means that amwell ownership is distributed among various shareholders, including institutional investors and the public. This structure allows for a broader base of investors to participate in the company's growth.
| Board Member | Title | Class |
|---|---|---|
| Ido Schoenberg, MD | Chairman and CEO | N/A |
| Roy Schoenberg, MD, MPH | Executive Vice Chairman | N/A |
| Stephen Schlegel | Director | Class II |
| Dr. Delos (Toby) Cosgrove | Director | Class II |
| Rivka Goldwasser | Director | Class II |
The voting structure of the company is designed to give significant control to the founders. Each share of Class A and Class C common stock has one vote per share, with the exception that Class C common stock does not have voting rights for director elections. Holders of Class B common stock collectively possess 51% of the total voting power of all outstanding securities. Their votes are calculated as 1.0408163 times the total votes cast by Class A and Class C stockholders. This arrangement allows the founders to retain considerable influence over the company's strategic decisions. To learn more about the company's target audience, you can read this article about the Target Market of amwell.
Voting Power and Influence
The voting structure gives founders significant influence. Class B shareholders hold 51% of the total voting power. This concentrated control impacts the company's strategic direction.
- Ido Schoenberg, MD, is the Chairman and CEO.
- Roy Schoenberg, MD, MPH, is the Executive Vice Chairman.
- Recent director nominees include Stephen Schlegel, Dr. Delos (Toby) Cosgrove, and Rivka Goldwasser.
- Rivka Goldwasser was recommended for her expertise in health technology and finance.
amwell Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped amwell’s Ownership Landscape?
Over the past few years, several key developments have reshaped the ownership landscape of the amwell company. In July 2024, the company implemented a 1-for-20 reverse stock split to meet the New York Stock Exchange's minimum average closing price requirement. This action significantly reduced the number of outstanding shares, impacting the ownership structure directly. This move was a strategic financial maneuver to maintain its listing on the NYSE.
Leadership transitions have also influenced the amwell ownership profile. Roy Schoenberg, co-founder, shifted from his dual role to become Executive Vice Chairman of the Board in June 2024, with Ido Schoenberg taking over as the sole CEO. These changes at the executive level often reflect shifts in strategic direction and can impact investor confidence and, consequently, amwell stock performance.
| Metric | Year | Value |
|---|---|---|
| Total Revenue | 2024 | $254.4 million |
| Net Loss | 2024 | $212.6 million |
| Revenue Forecast | 2025 | $250-$260 million |
Financially, amwell reported a total revenue of $254.4 million for 2024, with a net loss of $212.6 million. The company anticipates revenue between $250 million and $260 million for 2025, factoring in the divestiture of Amwell Psychiatric Care. The strategic goal is to achieve positive cash flow by 2026. Furthermore, insider trading activities, such as director Deborah C. Jackson selling shares to cover tax liabilities, provide insights into the perspectives of key stakeholders regarding the company's value and future prospects. To learn more about the company's strategic direction, consider exploring the Growth Strategy of amwell.
Reverse Stock Split
A 1-for-20 reverse stock split was executed in July 2024. This was done to meet the NYSE's minimum price requirement. The split reduced the number of outstanding shares significantly.
Leadership Changes
Roy Schoenberg transitioned to Executive Vice Chairman. Ido Schoenberg became the sole CEO in June 2024. Leadership shifts often signal strategic changes within the company.
Financial Performance
2024 revenue was $254.4 million with a net loss of $212.6 million. Revenue for 2025 is projected between $250-$260 million. The company aims for positive cash flow by 2026.
Insider Activity
Some directors sold shares to cover tax liabilities. Deborah C. Jackson sold shares in June 2024 at $0.4072 per share. This reflects insights into stakeholder perspectives.
amwell Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of amwell Company?
- What is Competitive Landscape of amwell Company?
- What is Growth Strategy and Future Prospects of amwell Company?
- How Does amwell Company Work?
- What is Sales and Marketing Strategy of amwell Company?
- What is Brief History of amwell Company?
- What is Customer Demographics and Target Market of amwell Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.